4D Molecular Therapeutics, Inc. Common Stock

FDMT · Biotechnology · $757.6M
Powering up
FDMT
$15.22
▲ +3.68%
09/18 O 15.12 H 15.69 L 14.78 C 15.22 ▲ +3.68%
Vol 1.8M RS 95
RS rating95
Now vs pivot (%)−10.10%
Tightening (ATR ratio)1.35×
Volume dry-up1.51×
Up/down volume, net0.16
From 52-week high10%
forming
Previous breakout stopped out ▼ −9.45% in Aug
Powering up
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

The read

The base has run 4.4 weeks and fell 24% from its ceiling at its deepest. The pivot is $16.93, and the stock closed 10.1% below it. Its relative strength rating is 95.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap
  1. Earningstentativein 53d
    Quarterly earnings
    Nov 10, 2026
Flagged by the market sweep
GappedTape · 2026-09-18
+6.7%

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means.

In the news

No headlines for this company in the last couple of weeks.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
4D Molecular Therapeutics, Inc. Common Stock (FDMT) — The Tape